LONDON - Tuesday, July 2nd 2013 [ME NewsWire] Building a better working world adopted as purpose EY adopted as global brand name New logo unveiled (BUSINESS WIRE)-- EY announced today that Mark Weinberger has become Global Chairman and CEO. The professional services organization also announced the adoption of EY as its global brand name, unveiled a new logo and adopted Building a better working world as its purpose. Mark, 51, has had a distinguished career with a track record of leadership both inside and outside of EY. Mark has previously served as the Global and Americas Head of Tax and on the Global and Americas Executive. He has been a senior advisory partner for many of EY’s largest clients and also served on the Global Markets Executive and Global Public Policy Committees. Mark was the Assistant Secretary of the US Treasury (Tax Policy) under President George W. Bush and he was appointed to the US
...
Read more »
|
DULUTH, Ga. - Tuesday, July 2nd 2013 [ME NewsWire] (BUSINESS WIRE)-- AGCO, Your Agriculture Company (NYSE: AGCO), a worldwide manufacturer and distributor of agricultural equipment, today named Eric Hansotia Senior Vice President, Global Harvesting and Advanced Technology Solutions. "We are very pleased to announce that Eric Hansotia has joined our executive team,” said Martin Richenhagen, Chairman, President and Chief Executive Officer of AGCO. "He will be responsible for a global team of professionals focused on the development, sales, product management and support for global harvesting equipment as well as for precision agriculture and connectivity technology for all AGCO machinery.” Mr. Hansotia has extensive Agricultural Industry experience in engineering, quality, advanced technology, manufacturing, product management and global business leadership. In his 20-year tenure with John Deere, his most recent role was Senior Vice President, Global Harvesting, where he le
...
Read more »
|
HIGH POINT, N.C. - Tuesday, July 2nd 2013 [ME NewsWire] (BUSINESS WIRE)-- TransTech Pharma Inc. announced today that it has successfully completed an End of Phase 2 meeting for TTP488 with the U.S. Food and Drug Administration (FDA). TTP488 is under development for the treatment of mild to moderate Alzheimer’s disease. The FDA Division of Neurology Products agreed that the data from the completed Phase 2 clinical trial is sufficient to support the start of a Phase 3 registration program. The FDA concurred with TransTech’s proposal for the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, the clinical pharmacology program and the plan to apply for a Special Protocol Assessment ("SPA"). The Phase 3 clinical trial design for TTP488 will focus on patients with mild to moderate Alzheimer’s disease. TransTech Pharma anticipates filing an SPA request within the next few weeks. "We are
...
Read more »
|
Spin-off from Covidien plc creates new global specialty pharmaceuticals company DUBLIN - Monday, July 1st 2013 [ME NewsWire] (BUSINESS WIRE)-- Mallinckrodt plc (NYSE: MNK) begins "regular-way” trading today on the New York Stock Exchange as an independent, global specialty pharmaceuticals company under the symbol MNK. Mallinckrodt completed its previously announced separation from Covidien plc (NYSE: COV) in a spin-off to shareholders on Friday, June 28. "Today marks a significant new chapter in Mallinckrodt’s proud history,” said Mark Trudeau, President and CEO of Mallinckrodt. "We are well positioned to leverage the skills and capabilities that have been developed over 145 years of pharmaceuticals industry experience. There are many benefits to our being independent that will accrue to Mallinckrodt’s shareholders, customers and employees going forward. We are excited about the growth opportunities that lie ahead.” Covidien announced in December 2011 that
...
Read more »
|
RESEARCH TRIANGLE PARK, N.C. - Monday, July 1st 2013 [BUSINESS WIRE/ ME NewsWire] (BUSINESS WIRE)-- Quintiles Transnational Holdings Inc. (NYSE: Q) will release its financial results for the second quarter of 2013 on Thursday, August 1, 2013, before the market opens. An investor conference call will be held on Thursday, August 1, 2013 at 8:00 a.m. EDT. To participate via telephone, please dial +1 (855) 484-7367 or +1 (631) 259-7541 outside the United States, approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible, live via webcast, on the Investor Relations section of the Quintiles website at www.quintiles.com. An archived edition of the conference call will be available online at www.quintiles.com after 1:00 p.m. EDT on Thursday, August 1. About Quintiles Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more t
...
Read more »
|
MARLBOROUGH, Mass. - Monday, July 1st 2013 [ME NewsWire] First Atypical Antipsychotic Indicated for the Treatment of Major Depressive Episodes Associated with Bipolar I Disorder (Bipolar Depression) Both as Monotherapy and as Adjunctive Therapy with Either Lithium or Valproate (BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for the use of Latuda® (lurasidone HCl) as 1) monotherapy and 2) adjunctive therapy with either lithium or valproate, both to treat adult patients with major depressive episodes associated with bipolar I disorder (bipolar depression).1 "These two approvals represent a significant milestone not only for Sunovion and DSP, but for the millions of Americans who are living with bipolar disorder and struggling to manage the symptoms of bipolar depression,” said Masayo Tada, Representative Director, President and Chief Executive Officer of Dainippon Sumito
...
Read more »
| |